AGA. A. Gulyaeva

A. A. Gulyaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. A. Gulyaeva has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative study of the quality of screening of donated blood for the presence of molecular markers of viral infections

    by О. Н. Мисько, D. S. Tikhomirov, T. A. Soldatova, R. M. Aguralieva, E. V. Kudinova, O. G. Makedonskaya, K. V. Vorobyova, G. D. Bochkova, L. M. Zubareva, E. L. Salimov, et al.

    Introduction. Transfusions of donor blood components are indispensable in providing medical care for a large number of conditions and diseases. Therefore, the issue of improving the quality and safety of transfusions is relevant for healthcare worldwide.Aim — to assess the quality of donor blood screening for HIV, HBV and HCV by PCR in several Russian blood banks.Methods: PCR, CLIA and ELISA.Results. A study was conducted to assess the quality of molecular screening of donated blood in medical organizations, which was carried out in two stages. Two different kits of control samples for each project stage were created and delivered to the project participants (blood banks). Each kit contained samples with or without HBV DNA / HIV RNA / HCV RNA. The first stage’s kit contained 40 samples, the second one — 10 samples. Thus, project participants performed 13 series of test runs (520 tests) on the first stage and 8 series of runs (80 tests) on the second one. The number kits copies sent to one participant was determined by the participant’s laboratory equipment. Participants who used the Cobas performed 330 tests, of which 255 were incorrect. Participants using the Procleix performed 40 tests, and 29 tests gave a false result. 140 samples were tested by AmpliSens, and results in 86 cases were incorrect. One participant used Vector-Best test kits and performed 40 tests, 16 of which returned incorrect. In total, 355 samples containing HBV DNA, 121 samples containing HCV RNA, and 82 samples containing HIV RNA were provided to project participants. HBV DNA was detected in 191 (53.8 %) of 355 samples, HCV RNA was detected in 119 (98.3 %) of 121 samples, and HIV RNA was detected in 76 (92.7 %) of 82 samples.Conclusion. The proportion of inconsistencies in the results increased depending on the decrease in the concentration of the marker being determined. Participants demonstrated the best performance results if they were using branded equipment. Such participants received the least inconsistencies. The biggest issue concerned HBV DNA detection due to a lower viremia of this pathogen. All samples with low HBV DNA levels contained anti-HBc, which indicates potential latent HBV. Therefore, it is appropriate to include anti-HBc in the routine screening of donated blood.


  • Open Access

    A comprehensive measures ensuring the safety of blood component transfusions

    by D. S. Tikhomirov, T. A. Tupoleva, A. A. Gulyaeva, O. G. Starkova, R. R. Abakarov, S. M. Kulikov, T. V. Gaponova

    Introduction. Human immunodefi ciency virus (HIV), Hepatitis B and C viruses (HBV, HCV) are the major blood-borne infections. Donor blood components cannot be currently replaced with synthetic substitutes, which determines the necessity of improving the viral safety of blood component transfusions.Aim.To describe a multicomponent system for monitoring the viral safety of donor blood component transfusions.General fi ndings.Measures ensuring the safety of blood component transfusions include the maintenance of regular communication with donors, pre-donation laboratory tests, viral screening, production, storage and clinical use of blood products, as well as monitoring of blood transfusion results. The selection of donors from low-risk behaviour groups ensures the viral safety of blood transfusion procedures at the initial stages of blood production. A necessary condition for improving the safety of transfusions is additional examination of donor blood samples for antibodies against the hepatitis B core antigen. Algorithms are described for investigating the initial occurrence of infectious markers in blood transfusion recipients, a retrospective investigation in cases where viral infection markers are identifi ed in recurrent donors, as well as for the monitoring of the virological status of patients with blood system disorders. The implementation of these measures can increase the overall safety of blood transfusion.


  • Open Access

    SUSTAINABLE TRENDS IN THE FREQUENCY OF HEMOTRANSMISSIVE INFECTIONS IN DONORS OF BLOOD AND ITS COMPONENTS

    by Tatyana A. Tupoleva, D. S. Tikhomirov, A. A. Gulyaeva, E. N. Ovchinnikova, M. V. Demin, T. V. Gaponova

    For past several years there is a sustained trend in reducing of viral hepatitis incidence (both acute and chronic), among public in general and among blood donors, according to epidemiological data. However, there is a lack of data either on other infections in blood donors or differences in infection markers’ patterns in primary or regular donors. The aim of the study was to show a sustained trend in reducing of infection markers identification frequency among primary and regular donors. Materials and methods. 103 716 blood samples were tested for infection markers using ELISA, CМIA and PCR. 39 514 samples from 10 354 donors are described in detail: 7654 - from primary donors and 31 860 - from regular donors. Age 18-70 yrs., median 33 yrs. Male/female - 6036/4318. Results and discussion. The trend was proved by 10-fold decrease in frequency of infection markers among blood donors. The detection rate of infection markers in regular donors was significant lower than in primary donors and in general population. Through 2015 to 2017 upraise of number of regular donors from 40,6% up to 65,4% was observed. The same was observed for donations from regular donors also: in 2015 primary/regular donors’ donation ratio was 1:2.4, in 2016 - 1:5.2, in 2017 - 1:6.6. Conclusion. For the last 8 years a stable decrease in frequency of blood-borne infections among donors has been observed, which is a result of several factors. Among these factors are: reduction of hepatitis B and C incidence in the Russian Federation, vaccination against hepatitis B program, blood management strategy implementation. A major impact can be attributed to blood productions from regular donors not the primary ones.